Dabur Pharma Forays Into Pak Aanti-cancer Drug Market (India)
This article was originally published in PharmAsia News
Executive Summary
Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan. "Increasingly, our focus is to expand not only in the developed markets but also in emerging ones. Recently we have started exporting our anti-cancer drugs to Pakistan," says Dabur Pharma Additional Director and Non-Executive Chairman Mohit Burman. The move follows the Pakistan government allowing imports of anti-cancer drugs from India, and the nation's health ministry has already granted permission to two companies, Atco Pharma and AJ Mirza Pharma to import from Dabur Pharma. Dabur Pharma has also started dispatches to Turkmenistan from its dosage form manufacturing unit at Baddi in Himachal Pradesh. Earlier this year, Dabur Pharma acquired the sales and distribution network of Thai firm Biosciences. Meanwhile, the company's drug Intaxel became the first ever generic oncology drug to cross 100 million Baht sales mark in the country. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.